J3L-MC-EZEJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524858-34-00

Enrollment

145

Registered

2026-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

Brief summary

Percent Change from Baseline in Noncalcified Plaque (NCP) Volume

Interventions

DRUGPlacebo to match LY

DRUGLepodisiran

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Percent Change from Baseline in Noncalcified Plaque (NCP) Volume	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 1, 2026